This work has been retracted.
Activation of Rac1 by Src-dependent phosphorylation of Dock180Y1811 mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans
Year: 2011
Type: article
Abstract: Two hallmarks of glioblastoma multiforme, the most common malignant brain cancer in humans, are aggressive growth and the ability of single glioma cells to disperse throughout the brain. These characteristics render tumors resistant to current therapies and account for the poor prognosis of patients. Although it is known that oncogenic signaling caused by overexpression of genes such as PDGFRA is responsible for robust glioma growth and cell infiltration, the mechanisms underlying glioblastoma malignancy remain largely elusive. Here, we report that PDGFRα signaling in glioblastomas leads to Src-dependent phosphorylation of the guanine nucleotide exchange factor Dock180 at tyrosine 1811 (Dock180(Y1811)) that results in activation of the GTPase Rac1 and subsequent cell growth and invasion. In human glioma cells, knockdown of Dock180 and reversion with an RNAi-resistant Dock180(Y1811F) abrogated, whereas an RNAi-resistant Dock180(WT) rescued, PDGFRα-promoted glioma growth, survival, and invasion. Phosphorylation of Dock180(Y1811) enhanced its association with CrkII and p130(Cas), causing activation of Rac1 and consequent cell motility. Dock180 also associated with PDGFRα to promote cell migration. Finally, phosphorylated Dock180(Y1811) was detected in clinical samples of gliomas and various types of human cancers, and coexpression of phosphorylated Dock180(Y1811), phosphorylated Src(Y418), and PDGFRα was predictive of extremely poor prognosis of patients with gliomas. Taken together, our findings provide insight into PDGFRα-stimulated gliomagenesis and suggest that phosphorylated Dock180(Y1811) contributes to activation of Rac1 in human cancers with PDGFRA amplification.
DOI: 10.1172/jci58559
Institutions: University of Pittsburgh, Sanford Burnham Prebys Medical Discovery Institute, Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital, State Key Laboratory of Experimental Hematology, United States Department of Veterans Affairs, Taichung Veterans General Hospital, Ludwig Cancer Research, Ludwig Cancer Research, Cell Signaling Technology (United States), Ludwig Cancer Research, Kyorin University, University of California San Diego, Mayo Clinic, Saitama Medical University
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
Funders: James S. McDonnell Foundation, National Foundation for Cancer Research, Pennsylvania Department of Health, Leukemia and Lymphoma Society, Goldhirsh Foundation, University of Pittsburgh, Hillman Foundation, National Natural Science Foundation of China, Saitama Medical University, National Institutes of Health, Cancer Institute, University of Pittsburgh, Japan Society for the Promotion of Science, National Key Research and Development Program of China, National Heart, Lung, and Blood Institute, National Cancer Institute, U.S. National Library of Medicine
Awards: G1085373467, Development of novel combined therapies with anti-EGFR monoclonal antibody and anticancer drug for malignant gliomas, Ontology-Driven Methods for Knowledge Acquisition and Knowledge Discovery, Angiopoietin-2 and Glioma Invasion, ELMO1, Dock180 and Glioma Invasion, Stem Cell Efficiency Regulated by CDK Inhibitors, G6966134840, Signaling Interactions in Cell Survival and Invasion, Mayo SPORE in Brain Cancer, G7950859287, Statistical methods for integromics discoveries, Genetics and Biology of Malignant Glioma, Cancer Center Support Grant, G948547148
OpenAlex ID: W2090826582
